On March 11, 2026, Drugs Made In America Acquisition II Corp. (the "Company") announced the issuance of an unsecured convertible note, referred to as the "Bridge Note," to Alpha Multi Family Office (the "Investor") for a principal amount of $150,000. This initial loan is part of a larger financing effort, with a total of $1,400,000 anticipated through a Convertible Notes Financing as outlined in a Letter of Intent (LOI) with the Investor. The Bridge Loan is intended to cover various expenses related to the Company's upcoming business combination, including accounting and audit costs. The Bridge Note has a maturity date set for nine months from issuance and does not accrue interest. Upon the completion of the Company's business combination, the Investor has the option to convert the outstanding principal into shares of the combined entity at a conversion price reflecting a 35% discount to the market price at the time of conversion. The Company plans to utilize the proceeds from this loan to ensure compliance with regulatory requirements and maintain its listing status. This financing move is seen as a strategic step to bolster the Company's operational capabilities as it prepares for its business combination, which is expected to enhance shareholder value and market positioning.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.